Stock listing

NASDAQ:PMVP PMV Pharmaceuticals, Inc. Stock

Home listing (NASDAQ) of PMV Pharmaceuticals, Inc.

Follow PMV Pharmaceuticals, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:PMVP

$0.876 USD -0.434 (-33.1%)

Close on Nov 20, 2026

Past year -33.1% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$0.660 – $1.340 USDNov 20, 2026
Volume
4.81M sharesNov 20, 2026
Market cap
$66.17M USDAt the close on Nov 20, 2026 · price × 75.53M shares outstanding
52-week range
$0.660 – $1.910 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$1.06M USDMedian day 468,500 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
PMV Pharmaceuticals, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:PMVP · Home$0.876 USD-0.434 (-33.1%)4,813,400$1.340$1.340$0.660$1.310Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:PMVP · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$0.876-0.434-33.1%$1.340$1.340$0.6604,813,400
$1.310+0.090+7.4%$1.240$1.330$1.2301,191,000
$1.2200.0000.0%$1.210$1.280$1.190430,800
$1.220+0.030+2.5%$1.220$1.230$1.070713,400
$1.190-0.080-6.3%$1.270$1.300$1.180585,600
$1.270+0.060+5.0%$1.220$1.270$1.190290,800
$1.210-0.050-4.0%$1.250$1.269$1.180353,400
$1.260+0.040+3.3%$1.230$1.270$1.230154,100
$1.220-0.030-2.4%$1.230$1.260$1.175584,800
$1.250-0.010-0.8%$1.270$1.310$1.240189,400
$1.260-0.015-1.2%$1.280$1.290$1.240194,300
$1.275-0.050-3.8%$1.300$1.300$1.200475,600
$1.325-0.055-4.0%$1.400$1.440$1.305529,800
$1.380+0.010+0.7%$1.370$1.420$1.330458,200
$1.370+0.060+4.6%$1.310$1.400$1.310440,400
$1.310-0.040-3.0%$1.330$1.331$1.2101,212,800
$1.350-0.030-2.2%$1.390$1.390$1.330238,100
$1.380+0.130+10.4%$1.250$1.390$1.220348,900
$1.250+0.120+10.6%$1.170$1.280$1.155375,169
$1.130-0.140-11.0%$1.260$1.285$1.100648,579
$1.270-0.035-2.7%$1.300$1.330$1.255171,000
$1.305-0.055-4.0%$1.360$1.370$1.300128,600
$1.360-0.030-2.2%$1.370$1.410$1.350236,600
$1.390+0.135+10.8%$1.260$1.410$1.260347,600
$1.255+0.045+3.7%$1.210$1.290$1.210196,000
$1.210-0.080-6.2%$1.280$1.300$1.200357,600
$1.290+0.050+4.0%$1.260$1.330$1.240376,600
$1.240-0.110-8.1%$1.330$1.370$1.230525,800
$1.350-0.060-4.3%$1.400$1.466$1.315541,300
$1.410-0.110-7.2%$1.550$1.550$1.400398,600
$1.520+0.030+2.0%$1.490$1.610$1.480891,700
$1.490-0.010-0.7%$1.510$1.540$1.460461,400
$1.500-0.110-6.8%$1.590$1.600$1.480607,400
$1.610-0.170-9.6%$1.780$1.810$1.591616,100
$1.780-0.010-0.6%$1.800$1.840$1.7001,185,500
$1.790+0.040+2.3%$1.750$1.870$1.6803,735,800
$1.750+0.080+4.8%$1.680$1.910$1.6301,647,200
$1.670+0.240+16.8%$1.440$1.725$1.4403,124,700
$1.430+0.070+5.1%$1.370$1.450$1.360550,900
$1.360+0.030+2.3%$1.340$1.390$1.300336,100
$1.330-0.005-0.4%$1.320$1.380$1.290271,200
$1.335-0.035-2.6%$1.360$1.400$1.280486,300
$1.370-0.140-9.3%$1.510$1.520$1.365570,700
$1.510+0.035+2.4%$1.470$1.525$1.460316,900
$1.475-0.025-1.7%$1.500$1.510$1.445330,000
$1.500+0.040+2.7%$1.460$1.520$1.4301,184,900
$1.460+0.030+2.1%$1.430$1.500$1.420430,800
$1.430+0.070+5.1%$1.370$1.510$1.3701,021,700
$1.360-0.100-6.8%$1.450$1.450$1.350705,400
$1.460+0.060+4.3%$1.420$1.495$1.3801,109,800
$1.400-0.040-2.8%$1.450$1.505$1.400538,600
$1.440+0.065+4.7%$1.340$1.450$1.340673,600
$1.375+0.035+2.6%$1.340$1.390$1.340419,100
$1.340+0.050+3.9%$1.310$1.375$1.2901,163,500
$1.290+0.050+4.0%$1.240$1.350$1.240530,000
$1.240-0.020-1.6%$1.260$1.289$1.199576,300
$1.260-0.030-2.3%$1.260$1.290$1.242704,300
$1.290+0.080+6.6%$1.150$1.310$1.1156,823,800
$1.210-0.010-0.8%$1.240$1.240$1.2101,115,500
$1.220-0.020-1.6%$1.250$1.250$1.21590,900
$1.240-0.070-5.3%$1.300$1.310$1.220197,500
$1.310+0.005+0.4%$1.300$1.320$1.29594,500
$1.3050.0000.0%$1.310$1.320$1.290211,700
$1.305-0.025-1.9%$1.340$1.360$1.300168,300
$1.330+0.030+2.3%$1.320$1.340$1.300131,300
$1.300+0.020+1.6%$1.290$1.350$1.270458,100
Ticker
NASDAQ:PMVP
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All PMV Pharmaceuticals, Inc. news

PMV Pharmaceuticals, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
13 in the last 12 months · 57 in all · newest Nov 20, 2026 · oldest 2020
Decks
5 decks · latest September 2026

Where PMV Pharmaceuticals, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:PMVP · Home listing · This pageNASDAQUnited StatesUSD
BOATS:PMVPBOATSUnited StatesUSD

Valuation

Price/book 1.2× against a median of 3.0×: the lowest of 9 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
−$36.25M USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
Negative EBITDA
Price/book
1.2×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.0×
Beta vs S&P 500
1.43

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
PMV Pharmaceuticals, Inc. · NASDAQ:PMVPUS$66.17M−US$36.25Mn/an/an/a1.2×n/a0.0×1.43
ABIONYX Pharma SA · EURONEXT:ABNXUS$68.36MUS$55.53Mn/a12.4×n/a4.0×−136.6%1.0×n/a
Cingulate Inc. · NASDAQ:CINGUS$67.48MUS$1.21Bn/an/an/a3.3×n/a56.0×1.41
Energenesis Biomedical Co., Ltd. · TWSE:6657US$67.22MUS$47.02Mn/a203×n/a3.1×n/a0.0×n/a
MediciNova, Inc. · NASDAQ:MNOVUS$67.11MUS$38.45Mn/a41.1×n/a1.6×n/a0.0×0.56
Dicot Pharma AB · OMXSTO:DICOTUS$66.56MUS$44.51Mn/an/an/a3.0×n/a0.0×n/a
Cardiff Oncology, Inc. · NASDAQ:CRDFUS$66.34MUS$32.82Mn/a58.7×n/a2.4×n/a0.0×1.32
Polaryx Therapeutics, Inc. · NASDAQ:PLYXUS$66.30MUS$57.86Mn/an/an/a8.7×n/a0.0×1.66
Gossamer Bio, Inc. · NASDAQ:GOSSUS$65.57MUS$55.23Mn/a0.7×n/an/a−159.5%n/a1.56
Tenaya Therapeutics, Inc. · NASDAQ:TNYAUS$65.32MUS$1.38Mn/a0.5×n/a1.2×n/a0.1×2.42
Atara Biotherapeutics, Inc. · NASDAQ:ATRAUS$64.49MUS$64.14Mn/a16.2×n/an/a−368.6%n/a1.43
Median of the othersUS$66.45MUS$51.12M16.2×3.0×−159.5%0.0×1.43

Forecasts

5 strong buy · Analysts' consensus from EODHD, read Nov 12, 2026. Not 6ix's view and not investment advice.

Price target
4.00 USD · Analysts' mean
EPS, year to Dec 2026
-1.35 · 1 analyst

Team and board

Officers

OfficerRole
David H. MackCo-Founder, President & CEO
Philip HermanChief Commercial Officer

Board

DirectorRole
Laurie StelzerChair, Board of Directors
Charles M BaumDirector
David H. MackCo-Founder, President & CEO
Matt EcklerDirector

Events

QuarterResultsShare move
Q3 2026Nov 10, 2026 · Before open−2.4%
Q2 2026Aug 14, 2026 · Before open+3.7%
Q1 2026May 12, 2026 · Before open+2.2%
Q4 2025Mar 5, 2026+9.3%
Q3 2025Nov 12, 2025 · Before open+6.8%
Q2 2025Aug 7, 2025 · Before open−4.6%
Q1 2025May 9, 2025 · Before open−0.1%
Q4 2024Feb 26, 2025 · After close−1.4%
Q3 2024Nov 7, 2024 · Before open+7.2%
Q2 2024Aug 8, 2024 · Before open0.0%
All 20 quarters
QuarterResultsShare move
Q1 2024May 9, 2024 · Before open−2.8%
Q4 2023Feb 29, 2024 · After close+1.4%
Q3 2023Nov 9, 2023 · Before open+2.1%
Q2 2023Aug 9, 2023 · Before open+27.7%
Q1 2023May 10, 2023 · Before open+8.3%
Q4 2022Mar 1, 2023 · Before open−14.2%
Q3 2022Nov 8, 2022 · Before open+1.1%
Q2 2022Aug 9, 2022 · Before open−8.1%
Q1 2022May 10, 2022 · Before open+9.7%
Q4 2021Mar 1, 2022 · Before open+5.1%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (September 2026)Investor deck27 slidesSeptember 2026
Investor Presentation (September 2025)Investor deck43 slidesSep 10, 2025
Technical Presentation (October 2023)Technical25 slidesOct 12, 2023
ASCO 2022 PC14586 Investor EventConference32 slidesJun 8, 2022
ASCO 2022Conference16 slidesJune 2022

Open Decks

Financings

RaiseDate
Public offering of common stock and accompanying warrants, or pre-funded warrants and accompanying warrants
Announced: about US$50.8M · US$1.21 a share · 1 warrant at US$1.21 for 60 months · TD Cowen
Dealers: TD Cowen (lead)
Sep 1, 2026

Open Financings · Read by 6ix AI from the company's releases

IPO

Priced at US$18.00 a share on Sep 24, 2020.

Price
US$18.00 a share
Shares offered
11,765,000 shares of common stock
Offering size
US$211.8 million
Underwriters' option
Up to 1,764,750 more shares
Underwriters
Goldman Sachs & Co. LLC, BofA Securities, Cowen, Evercore ISI · In the order on the cover

Steps

StepWhen
Draft sent to the SEC in confidenceJun 26, 2020
Filed publiclySep 4, 2020
Amended twiceNewest Sep 24, 2020
Shares registered with an exchangeSep 21, 2020
Declared effective by the SECSep 24, 2020
Final prospectus, with the priceSep 25, 2020

Open IPO · From the cover of the final prospectus (424B4) filed Sep 25, 2020

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Revenue00000000
Cost of revenue133.0K1.14M1.26M650.0K1.28M318.0K388.0K338.0K
Gross profit-133.0K-1.14M-1.26M-650.0K-1.28M-318.0K-388.0K-338.0K
Research and development69.9M58.5M55.9M52.0M36.5M23.9M20.8M13.9M
Selling, general and administrative16.3M26.9M24.2M25.1M21.8M11.0M5.88M5.04M
Operating income-86.2M-85.4M-80.1M-77.0M-58.3M-34.9M-26.6M-18.9M
Depreciation and amortization133.0K1.14M1.26M315.0K307.0K318.0K388.0K338.0K
EBITDA-86.1M-84.3M-78.9M-76.7M-58.0M-34.6M-26.2M-18.6M
Interest expense4.03M777.0K826.0K1.29M0
Income before tax-79.9M-74.8M-69.0M-73.3M-57.8M-34.4M-25.3M-17.5M
Income tax-2.17M-16.1M2.00K-9.00K23.0K6.00K8.00K3.00K
Net income-77.7M-58.7M-69.0M-73.3M-57.8M-34.4M-25.4M-17.5M
Earnings per share, basic-1.48-1.14-1.44-1.61-1.28-2.40-8.35-5.82
Earnings per share, diluted-1.48-1.14-1.44-1.61-1.28-2.40-8.35-5.82

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Cash and equivalents38.0M40.9M37.7M108.3M172.5M361.4M73.3M30.3M
Short-term investments75.0M128.6M165.4M132.8M124.7M028.2M31.6M
Current assets115.2M175.7M207.4M247.0M301.3M364.8M102.1M62.2M
Property, plant and equipment237.0K409.0K10.7M11.0M3.09M569.0K739.0K1.02M
Total assets116.6M191.3M252.2M270.3M331.6M365.5M103.0M63.5M
Accounts payable3.15M6.58M3.24M3.00M3.19M1.61M2.84M1.04M
Current liabilities11.4M14.4M14.0M10.8M12.2M6.41M4.52M2.33M
Total debt838.0K1.19M13.3M14.0M11.2M168.9M107.2M
Total liabilities11.8M15.2M26.5M24.3M23.0M6.41M4.57M109.6M
Shareholders' equity104.7M176.1M225.7M246.0M308.6M359.1M-70.5M-46.1M
Shares outstanding53.3M51.9M51.4M45.8M45.4M44.8M3.05M45.5M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Cash from operations-73.6M-51.3M-55.7M-63.8M-46.6M-32.7M-22.1M-15.2M
Capital spending-29.0K-655.0K-962.0K-7.98M-1.35M-148.0K-109.0K-452.0K
Free cash flow-73.6M-51.9M-56.6M-71.7M-47.9M-32.9M-22.2M-15.6M
Cash from investing70.2M53.4M-50.5M-1.37M-143.6M27.9M3.23M21.7M
Cash from financing505.0K313.0K35.6M958.0K2.02M293.0M61.8M61.8M
Share buybacks958.0K2.02M293.0M
Change in cash-2.89M2.35M-70.6M-64.2M-188.1M288.1M43.0M6.51M

Open Financials

Filings

FilingDateTypeFiled with
8-K · Current reportNov 20, 2026Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 16, 2026Big-stake noticeSEC
10-Q · Quarterly reportNov 10, 2026Quarterly reportSEC
8-K · Current reportNov 10, 2026ResultsSEC
4 · Change in ownershipOct 5, 2026Insider tradeSEC
3 · Initial statement of ownershipOct 5, 2026Insider tradeSEC
8-K · Current reportOct 5, 2026Management or board changeSEC
SCHEDULE 13G · Big-stake noticeSep 15, 2026Big-stake noticeSEC
8-K · Current reportSep 1, 2026Material contractSEC
424B5 · ProspectusSep 1, 2026Offer documentSEC
Show 200 filings
FilingDateTypeFiled with
424B3 · ProspectusAug 31, 2026Offer documentSEC
424B5 · ProspectusAug 31, 2026Offer documentSEC
8-K · Current reportAug 31, 2026Current reportSEC
10-Q · Quarterly reportAug 14, 2026Quarterly reportSEC
8-K · Current reportAug 14, 2026ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedJul 28, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedJul 10, 2026Big-stake noticeSEC
4 · Change in ownershipJun 5, 2026Insider tradeSEC
4 · Change in ownershipJun 5, 2026Insider tradeSEC
4 · Change in ownershipJun 5, 2026Insider tradeSEC
4 · Change in ownershipJun 5, 2026Insider tradeSEC
4 · Change in ownershipJun 5, 2026Insider tradeSEC
8-K · Current reportJun 5, 2026Meeting outcomeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
10-Q · Quarterly reportMay 12, 2026Quarterly reportSEC
8-K · Current reportMay 12, 2026ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 4, 2026Big-stake noticeSEC
ARS · Annual report to shareholdersApr 22, 2026Annual reportSEC
DEFA14A · Additional proxy materialApr 22, 2026Meeting noticeSEC
DEF 14A · Proxy statementApr 22, 2026Meeting noticeSEC
4 · Change in ownershipMar 9, 2026Insider tradeSEC
4 · Change in ownershipMar 9, 2026Insider tradeSEC
4 · Change in ownershipMar 9, 2026Insider tradeSEC
4 · Change in ownershipMar 9, 2026Insider tradeSEC
S-8 · Registration statement for employee plansMar 6, 2026Offer documentSEC
8-K · Current reportMar 6, 2026ResultsSEC
10-K · Annual reportMar 6, 2026Annual reportSEC
SCHEDULE 13D/A · Big-stake notice, amendedMar 4, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 17, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 9, 2026Big-stake noticeSEC
10-Q · Quarterly reportNov 12, 2025Quarterly reportSEC
8-K · Current reportNov 12, 2025ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 12, 2025Big-stake noticeSEC
4 · Change in ownershipOct 29, 2025Insider tradeSEC
4 · Change in ownershipOct 27, 2025Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedOct 27, 2025Big-stake noticeSEC
144 · Notice of proposed saleOct 23, 2025Other filingsSEC
SCHEDULE 13G · Big-stake noticeSep 23, 2025Big-stake noticeSEC
4 · Change in ownershipSep 12, 2025Insider tradeSEC
144 · Notice of proposed saleSep 10, 2025Other filingsSEC
8-K · Current reportSep 10, 2025Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 13, 2025Big-stake noticeSEC
10-Q · Quarterly reportAug 7, 2025Quarterly reportSEC
8-K · Current reportAug 7, 2025ResultsSEC
4 · Change in ownershipJul 3, 2025Insider tradeSEC
4 · Change in ownershipJul 3, 2025Insider tradeSEC
4 · Change in ownershipJul 3, 2025Insider tradeSEC
4 · Change in ownershipJul 3, 2025Insider tradeSEC
4 · Change in ownershipJun 9, 2025Insider tradeSEC
4 · Change in ownershipJun 9, 2025Insider tradeSEC
4 · Change in ownershipJun 9, 2025Insider tradeSEC
4 · Change in ownershipJun 9, 2025Insider tradeSEC
4 · Change in ownershipJun 9, 2025Insider tradeSEC
4 · Change in ownershipJun 9, 2025Insider tradeSEC
8-K · Current reportJun 9, 2025Meeting outcomeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2025Big-stake noticeSEC
10-Q · Quarterly reportMay 9, 2025Quarterly reportSEC
8-K · Current reportMay 9, 2025ResultsSEC
ARS · Annual report to shareholdersApr 25, 2025Annual reportSEC
DEFA14A · Additional proxy materialApr 25, 2025Meeting noticeSEC
DEF 14A · Proxy statementApr 25, 2025Meeting noticeSEC
3 · Initial statement of ownershipApr 23, 2025Insider tradeSEC
SCHEDULE 13G · Big-stake noticeApr 8, 2025Big-stake noticeSEC
4 · Change in ownershipMar 5, 2025Insider tradeSEC
4 · Change in ownershipMar 5, 2025Insider tradeSEC
4 · Change in ownershipMar 5, 2025Insider tradeSEC
10-K · Annual reportMar 3, 2025Annual reportSEC
8-K · Current reportMar 3, 2025ResultsSEC
SCHEDULE 13G · Big-stake noticeFeb 21, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 14, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeFeb 10, 2025Big-stake noticeSEC
S-8 · Registration statement for employee plansJan 28, 2025Offer documentSEC
4 · Change in ownershipJan 22, 2025Insider tradeSEC
SC 13G · Big-stake noticeDec 12, 2024Big-stake noticeSEC
EFFECT · Notice that a registration is effectiveNov 29, 2024Other filingsSEC
424B3 · ProspectusNov 27, 2024Offer documentSEC
CORRESP · Letter to the SECNov 25, 2024Other filingsSEC
UPLOAD · Letter from the SECNov 25, 2024Other filingsSEC
S-3 · Registration statementNov 20, 2024Offer documentSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
10-Q · Quarterly reportNov 7, 2024Quarterly reportSEC
8-K · Current reportNov 7, 2024ResultsSEC
4 · Change in ownershipOct 3, 2024Insider tradeSEC
4 · Change in ownershipOct 3, 2024Insider tradeSEC
4 · Change in ownershipOct 3, 2024Insider tradeSEC
4 · Change in ownershipSep 12, 2024Insider tradeSEC
4 · Change in ownershipSep 12, 2024Insider tradeSEC
SC TO-I/AAug 14, 2024Acquisition or disposalSEC
10-Q · Quarterly reportAug 8, 2024Quarterly reportSEC
8-K · Current reportAug 8, 2024ResultsSEC
SC TO-IJul 16, 2024Acquisition or disposalSEC
SC 13G/A · Big-stake notice, amendedJul 8, 2024Big-stake noticeSEC
4 · Change in ownershipJun 10, 2024Insider tradeSEC
4 · Change in ownershipJun 10, 2024Insider tradeSEC
4 · Change in ownershipJun 10, 2024Insider tradeSEC
4 · Change in ownershipJun 10, 2024Insider tradeSEC
4 · Change in ownershipJun 10, 2024Insider tradeSEC
4 · Change in ownershipJun 10, 2024Insider tradeSEC
8-K · Current reportJun 7, 2024Meeting outcomeSEC
10-Q · Quarterly reportMay 9, 2024Quarterly reportSEC
8-K · Current reportMay 9, 2024ResultsSEC
ARS · Annual report to shareholdersApr 24, 2024Annual reportSEC
DEFA14A · Additional proxy materialApr 24, 2024Meeting noticeSEC
DEF 14A · Proxy statementApr 24, 2024Meeting noticeSEC
SC 13G/A · Big-stake notice, amendedApr 9, 2024Big-stake noticeSEC
10-K · Annual reportFeb 29, 2024Annual reportSEC
8-K · Current reportFeb 29, 2024ResultsSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeFeb 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 13, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedJan 29, 2024Big-stake noticeSEC
S-8 · Registration statement for employee plansJan 24, 2024Offer documentSEC
SC 13G/A · Big-stake notice, amendedJan 23, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedJan 23, 2024Big-stake noticeSEC
4 · Change in ownershipJan 22, 2024Insider tradeSEC
4 · Change in ownershipJan 22, 2024Insider tradeSEC
4 · Change in ownershipJan 22, 2024Insider tradeSEC
8-K · Current reportJan 18, 2024Current reportSEC
3 · Initial statement of ownershipJan 11, 2024Insider tradeSEC
8-K · Current reportJan 5, 2024Management or board changeSEC
4 · Change in ownershipNov 24, 2023Insider tradeSEC
144 · Notice of proposed saleNov 22, 2023Other filingsSEC
4 · Change in ownershipNov 13, 2023Insider tradeSEC
10-Q · Quarterly reportNov 9, 2023Quarterly reportSEC
8-K · Current reportNov 9, 2023ResultsSEC
8-K · Current reportOct 12, 2023Current reportSEC
8-K · Current reportOct 11, 2023Current reportSEC
4 · Change in ownershipSep 18, 2023Insider tradeSEC
4 · Change in ownershipSep 18, 2023Insider tradeSEC
SC 13D/A · Big-stake notice, amendedAug 23, 2023Big-stake noticeSEC
10-Q · Quarterly reportAug 9, 2023Quarterly reportSEC
8-K · Current reportAug 9, 2023ResultsSEC
4 · Change in ownershipAug 8, 2023Insider tradeSEC
SC 13G/A · Big-stake notice, amendedJul 7, 2023Big-stake noticeSEC
4 · Change in ownershipJun 12, 2023Insider tradeSEC
4 · Change in ownershipJun 12, 2023Insider tradeSEC
4 · Change in ownershipJun 12, 2023Insider tradeSEC
4 · Change in ownershipJun 12, 2023Insider tradeSEC
4 · Change in ownershipJun 12, 2023Insider tradeSEC
4 · Change in ownershipJun 12, 2023Insider tradeSEC
8-K · Current reportJun 9, 2023Meeting outcomeSEC
SC 13G · Big-stake noticeMay 19, 2023Big-stake noticeSEC
4 · Change in ownershipMay 15, 2023Insider tradeSEC
4 · Change in ownershipMay 15, 2023Insider tradeSEC
4 · Change in ownershipMay 15, 2023Insider tradeSEC
4 · Change in ownershipMay 15, 2023Insider tradeSEC
SC 13G/A · Big-stake notice, amendedMay 10, 2023Big-stake noticeSEC
10-Q · Quarterly reportMay 10, 2023Quarterly reportSEC
8-K · Current reportMay 10, 2023ResultsSEC
EFFECT · Notice that a registration is effectiveMay 1, 2023Other filingsSEC
ARS · Annual report to shareholdersApr 28, 2023Annual reportSEC
DEFA14A · Additional proxy materialApr 28, 2023Meeting noticeSEC
8-K · Current reportApr 28, 2023Current reportSEC
DEF 14A · Proxy statementApr 28, 2023Meeting noticeSEC
POS AM · Amendment to an effective registrationMar 1, 2023Offer documentSEC
10-K · Annual reportMar 1, 2023Annual reportSEC
8-K · Current reportMar 1, 2023ResultsSEC
POSASRMar 1, 2023Other filingsSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2023Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2023Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2023Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2023Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 10, 2023Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 10, 2023Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 9, 2023Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedJan 31, 2023Big-stake noticeSEC
4 · Change in ownershipJan 30, 2023Insider tradeSEC
SC 13G/A · Big-stake notice, amendedJan 25, 2023Big-stake noticeSEC
S-8 · Registration statement for employee plansJan 24, 2023Offer documentSEC
SC 13G/A · Big-stake notice, amendedJan 24, 2023Big-stake noticeSEC
4 · Change in ownershipNov 8, 2022Insider tradeSEC
3 · Initial statement of ownershipNov 8, 2022Insider tradeSEC
10-Q · Quarterly reportNov 8, 2022Quarterly reportSEC
8-K · Current reportNov 8, 2022ResultsSEC
8-K · Current reportNov 4, 2022Management or board changeSEC
4 · Change in ownershipSep 13, 2022Insider tradeSEC
4 · Change in ownershipSep 13, 2022Insider tradeSEC
10-Q · Quarterly reportAug 9, 2022Quarterly reportSEC
8-K · Current reportAug 9, 2022ResultsSEC
SC 13G · Big-stake noticeJul 11, 2022Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedJul 7, 2022Big-stake noticeSEC
SC 13G · Big-stake noticeJun 17, 2022Big-stake noticeSEC
8-K · Current reportJun 8, 2022Current reportSEC
4 · Change in ownershipJun 6, 2022Insider tradeSEC
4 · Change in ownershipJun 6, 2022Insider tradeSEC

This page holds 200 of 394 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from PMV Pharmaceuticals, Inc.’s releases · as of Nov 10, 2026

Common shares
75,534,742
Fully diluted
75,534,742

Fully diluted

LineSharesAs of
Common shares75,534,742Nov 10, 2026

Share count over time

CountShares
Nov 10, 202675,534,742

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
BML Capital Management, LLC7.33M9.7%US$12.2MSep 30, 2026
Tang Capital Management LLC7.29M9.6%US$12.2MSep 30, 2026
Samsara Biocapital, LLC7.24M9.6%US$12.1MSep 30, 2026
Sio Capital Management, LLC3.63M4.8%US$6.07MSep 30, 2026
Vanguard3.41M4.5%US$5.69MSep 30, 2026
ADAR1 Capital Management, LLC2.7M3.6%US$4.51MSep 30, 2026
Euclidean Capital LLC2.63M3.5%US$4.39MSep 30, 2026
Two Sigma2.43M3.2%US$4.06MSep 30, 2026
Adage Capital Partners Gp, L.L.C.2.36M3.1%US$3.94MSep 30, 2026
Acadian Asset Management LLC2.29M3.0%US$3.81MSep 30, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
Boxer Capital Management, LLC2.05M2.7%US$3.42MSep 30, 2026
Eversept Partners, LP1.96M2.6%US$3.28MSep 30, 2026
Affinity Asset Advisors, LLC1.75M2.3%US$2.92MSep 30, 2026
ArrowMark Colorado Holdings LLC1.69M2.2%US$2.83MSep 30, 2026
Millennium1.46M1.9%US$2.44MSep 30, 2026
BlackRock917K1.2%US$1.53MSep 30, 2026
BIT Capital GmbH714K0.95%US$1.19MSep 30, 2026
Geode Capital500K0.66%US$836KSep 30, 2026
Aldebaran Capital, LLC490K0.65%US$818KSep 30, 2026
Walleye Capital LLC487K0.64%US$814KSep 30, 2026
Bridgeway Capital Management, LLC428K0.57%US$714KSep 30, 2026
Assenagon Asset Management S.A.329K0.44%US$549KSep 30, 2026
Citadel268K0.36%US$448KSep 30, 2026
Bank of America266K0.35%US$444KSep 30, 2026
Marshall Wace, LLP221K0.29%US$369KSep 30, 2026
State Street183K0.24%US$306KSep 30, 2026
RBF Capital, LLC162K0.21%US$271KSep 30, 2026
Goldman Sachs157K0.21%US$262KSep 30, 2026
MAI Capital Management133K0.18%US$222KSep 30, 2026
Susquehanna131K0.17%US$218KSep 30, 2026
Connor, Clark & Lunn Investment Management Ltd.110K0.15%US$184KSep 30, 2026
Hrt Financial LP103K0.14%US$172KSep 30, 2026
Rangeley Capital, LLC99,2400.13%US$166KSep 30, 2026
Northern Trust93,0470.12%US$155KSep 30, 2026
Ikarian Capital, LLC89,1360.12%US$149KSep 30, 2026
Empowered Funds, LLC75,5750.10%US$126KSep 30, 2026
Accurate Wealth Management, LLC50,0000.07%US$70,500Sep 30, 2026
Jacobs Levy Equity Management, Inc35,8170.05%US$59,814Sep 30, 2026
HSBC30,8910.04%US$49,117Sep 30, 2026
Barclays27,5360.04%US$45,985Sep 30, 2026
Gsa Capital Partners LLP27,3820.04%US$46,000Sep 30, 2026
Boothbay Fund Management, LLC27,1260.04%US$45,300Sep 30, 2026
Quadrature Capital Ltd23,7560.03%US$39,673Sep 30, 2026
Point72 Asset Management, L.P.18,8190.02%US$31,428Sep 30, 2026
Pathstone Holdings, LLC17,4870.02%US$29,203Sep 30, 2026
Corient Private Wealth LP15,0000.02%US$25,050Sep 30, 2026
Jane Street14,2450.02%US$23,789Sep 30, 2026
Morgan Stanley13,7190.02%US$22,911Sep 30, 2026
Sand Hill Global Advisors, LLC12,5390.02%US$20,940Sep 30, 2026
Independent Advisor Alliance12,5000.02%US$20,875Sep 30, 2026

This page holds 50 of 63 holders. Open Shareholders

Funds

HolderSharesOf the companyValueAs of
Vanguard Total Stock Market Index Fund1.49M2.0%US$1.99MJun 30, 2026
Meridian Small Cap Growth Fund1.06M1.4%US$1.42MJun 30, 2026
Vanguard Extended Market Index Fund452K0.60%US$606KJun 30, 2026
Ultra-Small Company Fund331K0.44%US$444KJun 30, 2026
Fidelity Extended Market Index Fund233K0.31%US$279KMay 31, 2026
iShares Micro-Cap ETF161K0.21%US$215KJun 30, 2026
Ultra-Small Company Market Fund76,9000.10%US$103KJun 30, 2026
Goldman Sachs Absolute Return Tracker Fund74,0500.10%US$99,227Jun 30, 2026
Fidelity Total Market Index Fund71,1900.09%US$85,428May 31, 2026
Fidelity Series Total Market Index Fund59,9240.08%US$71,909May 31, 2026
All 23 holders
HolderSharesOf the companyValueAs of
Vanguard Institutional Total Stock Market Index Fund45,0450.06%US$60,360Jun 30, 2026
Fidelity Nasdaq Composite Index Fund43,1380.06%US$51,766May 31, 2026
Tiff Multi-Asset Fund41,9120.06%US$56,162Jun 30, 2026
Vanguard Balanced Index Fund27,5470.04%US$36,913Jun 30, 2026
NVIT Small Cap Value Fund14,4960.02%US$19,425Jun 30, 2026
Multi-Manager Small Cap Equity Strategies Fund13,2370.02%US$15,884May 31, 2026
Diversified Equity Alpha Master Portfolio13,1670.02%US$17,644Jun 30, 2026
Blackstone Alternative Multi-Strategy Fund11,7000.02%US$15,678Jun 30, 2026
1290 VT Micro Cap Portfolio10,7220.01%US$14,367Jun 30, 2026
NVIT Multi-Manager Small Company Fund7,8910.01%US$10,574Jun 30, 2026
Avantis Total Equity Markets ETF4,716<0.01%US$5,659May 31, 2026
LVIP Dimensional U.S. Core Equity 1 Fund356<0.01%US$477Jun 30, 2026
Knights of Columbus U.S. ALL CAP INDEX FUND295<0.01%US$327Jul 31, 2026

Big stakes

StakeStakeSharesDateFiling
Tang Capital Management LLC9.99%7.57MSep 30, 2026Schedule 13G
Srinivas Akkaraju9.90%7.58MSep 2, 2026Schedule 13G
BML Investment Partners, L.P.9.90%5.29MDec 31, 2025Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Carol G. Gallagher
Other companies: TRex Bio, Inc. (Lead Independent Director · Since at least Nov 5, 2026); Atara Biotherapeutics, Inc. (Director · Since at least Jun 27, 2019); Certara, Inc. (Director · Jun 15, 2021 – Jun 15, 2021 · Past); Frazier Lifesciences Acquisition Corp (Director · Dec 8, 2020 – Nov 22, 2022 · Past); Metacrine Inc (Director · Sep 15, 2020 – Sep 15, 2020 · Past); Annexon, Inc. (Director · Jul 23, 2020 – Jul 23, 2020 · Past); Turning Point Therapeutics Inc (Director · Jul 24, 2019 – Aug 17, 2022 · Past); Tempest Therapeutics, Inc. (Director · Jun 20, 2019 – Jun 22, 2020 · Past)
Director · Since at least Nov 3, 2022
Richard Heyman
Other companies: Enliven Therapeutics, Inc. (Director · Since at least Feb 23, 2023); ORIC Pharmaceuticals, Inc. (Chairman · Since at least Apr 23, 2020); RayzeBio, Inc. (Director · Sep 14, 2023 – Feb 26, 2024 · Past); Kineta Inc. (Director · Dec 22, 2020 – Jun 2, 2021 · Past); Metacrine Inc (Director · Sep 15, 2020 – May 18, 2022 · Past); Tango Therapeutics, Inc. (Director · Sep 2, 2020 – Sep 2, 2020 · Past); Gritstone bio, Inc. (Director · Sep 27, 2018 – Jun 17, 2022 · Past)
Director · Since at least Sep 24, 2020
Arnold L Oronsky
Other companies: KalVista Pharmaceuticals, Inc. (Director · Nov 21, 2016 – Oct 1, 2020 · Past); MacroGenics, Inc. (Director · Oct 9, 2013 – Feb 18, 2014 · Past); Tesaro Inc (Director · Jun 27, 2012 – Aug 7, 2018 · Past); Anesiva Inc (Director · Jun 22, 2006 – May 9, 2008 · Past); Myogen Inc (Director · May 4, 2006 – Nov 13, 2006 · Past); Dynavax Technologies Corporation (Director · Feb 23, 2006 – May 28, 2020 · Past)
Director · Sep 24, 2020 – Sep 25, 2020 · Past
Charles Baum
Other companies: Acrivon Therapeutics, Inc. (Director · Since at least Jun 22, 2023); Poseida Therapeutics Inc (Director · May 16, 2022 – Jan 8, 2025 · Past); Tango Therapeutics, Inc. (Director · Sep 2, 2020 – Sep 2, 2020 · Past); Immunomedics Inc (Director · Feb 23, 2019 – Oct 23, 2020 · Past)
Director · Since at least Apr 1, 2021
Laurie Stelzer
Other companies: MBX Biosciences, Inc. (Director · Since at least Jan 20, 2026); Sionna Therapeutics, Inc. (Director · Since at least Feb 6, 2025); Spyre Therapeutics, Inc. (Chair of the Audit Committee · Since at least Nov 22, 2023); Surface Oncology Inc (Director · Jun 8, 2022 – Jun 8, 2022 · Past)
Chair, Board of Directors · Since at least Jun 2, 2022
Thilo Schroeder
Other companies: ARS Pharmaceuticals, Inc. (Director · Dec 3, 2020 – Dec 8, 2020 · Past); Revolution Medicines, Inc. (Director · Feb 12, 2020 – Dec 5, 2024 · Past); IDEAYA Biosciences, Inc. (Director · May 22, 2019 – May 22, 2019 · Past)
Director · Sep 24, 2020 – Oct 6, 2021 · Past
Winston Kung
Other companies: Corbus Pharmaceuticals Holdings, Inc. (Director · Since at least Aug 16, 2024); ArriVent BioPharma, Inc. (Chief Financial Officer · Since at least Jan 25, 2024); Janux Therapeutics, Inc. (Director · Since at least Sep 21, 2022)
COO, CFO · Sep 24, 2020 – May 12, 2023 · Past
David H. Mack
Other companies: Aduro Biotech Inc (Director · Feb 19, 2019 – May 5, 2020 · Past); Aerie Pharmaceuticals Inc. (Director · Oct 25, 2013 – Oct 25, 2013 · Past)
Co-Founder, President & CEO · Since at least Sep 24, 2020
Arnold J Levine
Other companies: MeiraGTx Holdings plc (Director · Jun 19, 2019 – Jun 7, 2022 · Past)
Director · Since at least Sep 24, 2020
Kirsten Flowers
Other companies: Kura Oncology, Inc. (CCO & Chief Strategy Officer · Jan 6, 2020 – Jan 27, 2023 · Past)
Director · Since at least Jan 5, 2022
All 16 people
PersonSeat
Robert Ticktin
Other companies: EPIRUS Biopharmaceuticals Inc (General Counsel · Jul 15, 2014 – May 27, 2016 · Past)
General Counsel & COO · Since at least Apr 21, 2025
Matt EcklerDirector · Since Oct 5, 2026 · Appointed, no departure found
Matt EcklerDirector · Since at least Oct 5, 2026
Michael CarulliChief Financial Officer · Since at least Jan 5, 2024
Philip HermanChief Commercial Officer · Since Sep 8, 2026 · Appointed, no departure found
Philip HermanChief Commercial Officer · Since at least Sep 8, 2026

Open People

Log in to ask 6ix AI your own questions about PMV Pharmaceuticals, Inc.